NCT06064864View on ClinicalTrials.gov

Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Crohn's Disease
Interventions
DRUG

Infliximab-Dyyb

Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Kyung Hee University Hospital

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

lead

Asan Medical Center

OTHER

NCT06064864 - Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD | Biotech Hunter | Biotech Hunter